This page is part of the Genetic Reporting Implementation Guide (v3.0.0-ballot: STU 3 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. The current version which supersedes this version is 2.0.0. For a full list of available versions, see the Directory of published versions
Generated Narrative: Observation
Resource Observation "ROS1-Fusion-therapuTrial"
Profile: Therapeutic Implication
status: final
category: Laboratory (Observation Category Codes#laboratory), Genetics (diagnosticServiceSectionId#GE)
code: Therapeutic Implication (To Be Determined Codes#therapeutic-implication)
subject: Patient/somaticPatient " HAMSBURG"
effective: 2023-02-01
performer: Practitioner/pathologistPractitioner " DOLIN"
derivedFrom: Observation/ROS1-Fusion-var
component
code: Associated phenotype (LOINC#81259-4)
value: Non-small cell lung cancer (SNOMED CT#254637007 "Non-small cell lung cancer (disorder)")
component
code: Medication assessed (LOINC#51963-7)
value: Taletrectinib ()
component
code: Associated Therapy (To Be Determined Codes#associated-therapy)
value: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors (clinicaltrials.gov#NCT04919811 "NCT04919811")
component
Related Artifact for Observation component:
code: Level of evidence (LOINC#93044-6)
value: Tier I - Level A ()